Cargando…
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatiti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624167/ https://www.ncbi.nlm.nih.gov/pubmed/26503519 http://dx.doi.org/10.1186/s12879-015-1208-1 |
_version_ | 1782397787469512704 |
---|---|
author | Kieran, Jennifer Ann Norris, Suzanne O’Leary, Aisling Walsh, Cathal Merriman, Raphael Houlihan, D. McCormick, P. Aiden McKiernan, Susan Bergin, Colm Barry, Michael |
author_facet | Kieran, Jennifer Ann Norris, Suzanne O’Leary, Aisling Walsh, Cathal Merriman, Raphael Houlihan, D. McCormick, P. Aiden McKiernan, Susan Bergin, Colm Barry, Michael |
author_sort | Kieran, Jennifer Ann |
collection | PubMed |
description | BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs. METHODS: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment. Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis related group costs. Non-parametric bootstrapping was performed to derive mean and 95%CI values. RESULTS: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was €136 (€3.60 SD). The cost of a Hepatitis C nursing review was €128 (€7.30 SD). The annual mean costs of care were as follows (95%CI): Mild €398 (€336, €482), Moderate €417(€335, €503), Compensated cirrhosis €1790 (€990, €3164), Decompensated cirrhosis €8302 (€3945, €14,637), Transplantation Year 1 €137,176 (€136,024, €138,306), Transplantation after Year 1 €5337 (€4942, €5799), Hepatocellular carcinoma €21,992 (€15,222, €29,467), Sustained virological response €44 (€16, €73). CONCLUSIONS: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were low in comparison to patients with chronic infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1208-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4624167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46241672015-10-29 Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study Kieran, Jennifer Ann Norris, Suzanne O’Leary, Aisling Walsh, Cathal Merriman, Raphael Houlihan, D. McCormick, P. Aiden McKiernan, Susan Bergin, Colm Barry, Michael BMC Infect Dis Research Article BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs. METHODS: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment. Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis related group costs. Non-parametric bootstrapping was performed to derive mean and 95%CI values. RESULTS: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was €136 (€3.60 SD). The cost of a Hepatitis C nursing review was €128 (€7.30 SD). The annual mean costs of care were as follows (95%CI): Mild €398 (€336, €482), Moderate €417(€335, €503), Compensated cirrhosis €1790 (€990, €3164), Decompensated cirrhosis €8302 (€3945, €14,637), Transplantation Year 1 €137,176 (€136,024, €138,306), Transplantation after Year 1 €5337 (€4942, €5799), Hepatocellular carcinoma €21,992 (€15,222, €29,467), Sustained virological response €44 (€16, €73). CONCLUSIONS: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were low in comparison to patients with chronic infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1208-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-26 /pmc/articles/PMC4624167/ /pubmed/26503519 http://dx.doi.org/10.1186/s12879-015-1208-1 Text en © Kieran et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kieran, Jennifer Ann Norris, Suzanne O’Leary, Aisling Walsh, Cathal Merriman, Raphael Houlihan, D. McCormick, P. Aiden McKiernan, Susan Bergin, Colm Barry, Michael Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title_full | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title_fullStr | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title_full_unstemmed | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title_short | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
title_sort | hepatitis c in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis c; a cross-sectional study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624167/ https://www.ncbi.nlm.nih.gov/pubmed/26503519 http://dx.doi.org/10.1186/s12879-015-1208-1 |
work_keys_str_mv | AT kieranjenniferann hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT norrissuzanne hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT olearyaisling hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT walshcathal hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT merrimanraphael hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT houlihand hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT mccormickpaiden hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT mckiernansusan hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT bergincolm hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy AT barrymichael hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy |